{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"23","value":"16"},{"groupId":"OG001","lowerLimit":"10","upperLimit":"58","value":"16"}]}],"title":"Median time for platelet recovery"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"18","value":"12"},{"groupId":"OG001","lowerLimit":"9","upperLimit":"35","value":"12"}]}],"title":"Median time for neutrophil recovery"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Peripheral blood progenitor cells were collected with either chemo-mobilization (27 of 39, 69%) or growth factor mobilization (12 of 39, 31%). Patients received an average of 9.0 × 10\\^6/kg CD34+ cells (range, 2.3-65) as their transplant graft.","dispersionType":"Full Range","groups":[{"description":"All patients received melphalan (100 mg/m\\^2/day × 2; days\n\n-3 and -2), for a total dose of 200 mg/m\\^2. Patients were randomized to receive bortezomib 24 hours before administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg/m\\^2","id":"OG000","title":"Bortezomib Before HD Melphalan"},{"description":"patients received melphalan (100 mg/m\\^2/day × 2; days\n\n-3 and -2), for a total dose of 200 mg/m\\^2. Patients were randomized to receive bortezomib 24 hours after administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg/m\\^2","id":"OG001","title":"Bortezomib After HD melphalanAll"}],"paramType":"MEDIAN","populationDescription":"As per the protocol","reportingStatus":"POSTED","timeFrame":"Day 30 after transplant","title":"Safety and Engraftment","type":"PRIMARY","unitOfMeasure":"days"}